Cystic Fibrosis – Pipeline Review, Status, Opportunities, Market Forecasts H1 2016

“The Report Cystic Fibrosis – Pipeline Review, H1 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

Global Markets Directs, Cystic Fibrosis – Pipeline Review, H1 2016, provides an overview of the Cystic Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Download Sample copy of this Report at:


– The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis

– The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects

– The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Follow us on LinkedIn:

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Cystic Fibrosis Overview 12

Therapeutics Development 13

Pipeline Products for Cystic Fibrosis – Overview 13

Pipeline Products for Cystic Fibrosis – Comparative Analysis 14

Cystic Fibrosis – Therapeutics under Development by Companies 15

Cystic Fibrosis – Therapeutics under Investigation by Universities/Institutes 21

Cystic Fibrosis – Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Unknown Stage Products 25

Cystic Fibrosis – Products under Development by Companies 26

Cystic Fibrosis – Products under Investigation by Universities/Institutes 34

Cystic Fibrosis – Companies Involved in Therapeutics Development 35

Actelion Ltd 35

Akari Therapeutics, Plc 36

Alaxia SAS 37

AlgiPharma AS 38

AmpliPhi Biosciences Corporation 39

Arcturus Therapeutics, Inc 40

Aridis Pharmaceuticals LLC 41

AstraZeneca Plc 42

Bayer AG 43

Boehringer Ingelheim GmbH 44

Calista Therapeutics, Inc. 45

Carolus Therapeutics, Inc. 46

Celtaxsys, Inc. 47

Chiesi Farmaceutici SpA 48

Cilian AG 49

Concert Pharmaceuticals, Inc. 50

Corbus pharmaceuticals, Inc. 51

CSA Biotechnologies LLC 52

Cyclacel Pharmaceuticals, Inc. 53

DiscoveryBiomed, Inc. 54

Editas Medicine, Inc. 55

Errant Gene Therapeutics, LLC 56

Galapagos NV 57

GlaxoSmithKline Plc 58

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074